

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/98306 A1

(51) International Patent Classification⁷: **C07D 491/06**,
A61K 31/435, C07D 491/04, A61P 1/00

(21) International Application Number: PCT/EP01/06749

(22) International Filing Date: 13 June 2001 (13.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00202180 6 22 June 2000 (22.06.2000) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE], Janssen
Pharmaceutica N.V., Patent Department, Turnhoutseweg
30, B-2340 Beerse (BE)

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VAN EMELLEN**,
Kristof [BE/BE], c/o Janssen Pharmaceutica N.V.,
Turnhoutseweg 30, B-2340 Beerse (BE) **DE BRUYN**,
Marcel, Frans, Leopold [BE/BE], c/o Janssen Phar-
maceutica N.V., Turnhoutseweg 30, B-2340 Beerse
(BE) **ALCÁZAR-VACA, Manuel, Jesús** [ES/ES], c/o
Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de
las Doce Estrellas, 5-7, Campo de las Naciones, E-28042

Madrid (ES) **ANDRÉS-GIL, José, Ignacio** [ES/ES], c/o
Janssen Cilag S.A., Edificio Johnson & Johnson, Paseo de
las Doce Estrellas, 5-7, Campo de las Naciones, E-28042
Madrid (ES) **FERNÁNDEZ-GADEA, Francisco, Javier**
[ES/ES], c/o Janssen Cilag S.A., Edificio Johnson &
Johnson, Paseo de las Doce Estrellas, 5-7, Campo de las
Naciones, E-28042 Madrid (ES) **MATESANZ-BALLES-**
TEROS, Maria, Encarnación [ES/ES], c/o Janssen Cilag
S.A., Edificio Johnson & Johnson, Paseo de las Doce Es-
trellas, 5-7, Campo de las Naciones, E-28042 Madrid (ES)
BARTOLOMÉ-NEBREDÁ, José, Manuel [ES/ES], c/o
Janssen Cilag S.A., Edificio Johnson & Johnson, Paseo de
las Doce Estrellas, 5-7, Campo de las Naciones, E-28042
Madrid (ES)







(74) Agent: **DE CORTE, Filip**; Janssen Pharmaceutica N.V.,
Turnhoutseweg 30, B-2340 Beerse (BE)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TL, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: COMPOUNDS FOR TREATING IMPAIRED FUNCTIONAL RELAXATION



(57) Abstract: The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein -a¹=a²-a³=a⁴- is a bivalent radical wherein one or two of a¹ to a⁴ are nitrogen and the remaining a¹ to a⁴ are -CH=, -Z¹-Z²- is a bivalent radical, -A- is a bivalent radical of formula -N(R⁶)-Alk²- or a 5, 6 or 7-membered saturated heterocycle containing one or two nitrogen atoms, R¹, R² and R³ are each independently selected from hydrogen, C₁₋₆alkyl, hydroxy, halo and the like. Alk¹ and Alk² are optionally substituted C₁₋₆alkanedyl. R⁵ is a radical of formula (d-1), (d-2), (d-3), (d-4), (d-5) wherein n is 1 or 2, p¹ is 0, and p² is 1 or 2, or p¹ is 1 or 2, and p² is 0, X is oxygen, sulfur or =NR⁹, Y² is oxygen or sulfur; R⁷ is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl or phenylmethyl, R⁸ is C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl or phenylmethyl, R⁹ is cyano, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkyloxycarbonyl or aminocarbonyl; R¹⁰ is hydrogen or C₁₋₆alkyl, and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to disturbed functional accommodation.